MZL
Lenalidomide, rituximab, and ibrutinib was effective as a first-line therapy for patients with follicular lymphoma and MZL.
Orelabrutinib induced high response rates and sustained remission in relapsed or refractory marginal zone lymphoma,
Axi-cel showed promising efficacy and safety in patients with relapsed or refractory indolent non-Hodgkin lymphomas.
Advertisement
Two surrogate markers predicted treatment effect on eight-year progression-free survival in patients with extranodal MZL.
The phase I/II study examined the use of the Bruton’s tyrosine kinase inhibitor in 385 patients.
Umbralisib was approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).
Advertisement
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.